• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

    JournalISSN 1078-1552eISSN 1477-092X中科院 医学 4区

    年发文量

    研究主题

    论文(3485)

    排序
    1Understanding Parental Perspectives on Chemotherapy Side Effects in Children with Cancer at Bugando Medical Centre, Mwanza, Tanzania: A Descriptive Cross-Sectional Study
    Deogratias M. Katabalo, Given Brown,Winfrida Minja, Baraka Fundo, Paul Sabuni,Stanley Mwita, Antony C. Liwa,Benson R. Kidenya,Kristin Schroeder

    Introduction Childhood cancer treatment often involves chemotherapy, which is associated with adverse drug reactions/side effects that require close monitoring. Parents and guardians play a critical role in identifying and managing these reactions in children. This study assessed the awareness, attitudes, and proactive monitoring practices of parents/guardians regarding chemotherapy-related adverse drug reactions among children with cancer at a tertiary referral hospital in Tanzania. Methods A descriptive cross-sectional study was conducted among 200 parents/guardians of paediatric cancer patients receiving chemotherapy at Bugando Medical Centre, Mwanza, Tanzania. Data were collected using a semi-structured questionnaire and analysed using Stata version 16. Descriptive statistics, chi-square tests, and logistic regression analyses were performed. Results Most participants demonstrated low awareness of chemotherapy-related adverse drug reactions (80.5%). However, positive attitudes (58.5%) and proactive monitoring practices (69.0%) were observed. Female caregivers were more likely to demonstrate proactive monitoring practices than male caregivers (AOR = 1.97, 95% CI: 1.05–3.68, p = 0.03). Participants who were aware of chemotherapy-related adverse drug reactions were also more likely to demonstrate proactive monitoring practices (AOR = 3.19, 95% CI: 1.22–8.35, p = 0.02). Conclusions Despite limited awareness, parents and guardians demonstrated positive attitudes and self-reported proactive monitoring of their children for chemotherapy-related adverse drug reactions. Strengthening caregiver education and communication during cancer treatment may improve awareness, facilitate early recognition, reporting and appropriate management of adverse reactions. Clinical trial Number NA.

    2026
    引用
    AI阅读
    加入学术空间
    2PembroPrep: Accelerating Efficiency and Minimizing Patient Chair Time
    Sarah Ritter, Jessie Rupp, Luke Bogdanovich, Patricia Roberts

    Introduction Prolonged infusion chair time negatively affects patient experience and limits operational capacity in outpatient oncology infusion settings. Advanced preparation and batching strategies reduce delays; however, the benefit of decentralized medication access has not been characterized. This study evaluated the impact of an anticipatory preparation strategy, scheduled batch preparation of pembrolizumab based on anticipated patient census data, with and without ADC point-of-care dispensing. Methods This single center, retrospective, pre-post study evaluated adult patients receiving pembrolizumab 200 mg monotherapy across three phases of operational changes: just-in-time compounding, after implementation of anticipatory preparation, and after anticipatory preparation plus ADC stocking in the infusion suite. The primary outcome was mean change in time from patient rooming to checkout. A secondary outcome was mean change in time from final product verification to medication administration. Outcomes were summarized using descriptive statistics and compared using one-way analysis of variance with Tukey's honestly significant difference tests. Results A total of 397 infusion encounters were analyzed. Mean rooming to checkout time decreased from 145.3 min at baseline to 140.4 min with anticipatory preparation and to 115.6 min following ADC stocking ( P = 0.0002). Mean dispense-to-administration time decreased from 19.5 min at baseline to 17.6 min with anticipatory preparation and to 6.7 min after ADC implementation (P < 0.001). Conclusions Anticipatory preparation of pembrolizumab was associated with modest reductions in medication administration time, while the addition of ADC stocking resulted in increased reduction of chair time. This approach may provide a scalable framework for improving operational efficiency in outpatient oncology infusion centers.

    2026
    引用
    AI阅读
    加入学术空间
    3BRAF Inhibitor Exposure During Pregnancy: A Systematic Review
    Kristina C. Hermanson, Casey L. Keller, Ryan M. Schuller, Aasmitha Mistry, Saeed K. Alzghari

    Objective BRAF inhibitors have been integrated into the treatment of several malignancies targeting the BRAF V600E-variant. However, there is limited evidence of the use of BRAF inhibitors in pregnancy. Hence, the purpose of this systematic review is to synthesize published reports evaluating the risk-benefit of BRAF inhibitor exposure during pregnancy. Methods A systematic search was conducted of PubMed, Scopus, Embase, Web of Science, and CINAHL Ultimate for articles published between January 1, 1966 and June 15, 2026. Included studies were those that involved women with a cancer diagnosis who received a BRAF inhibitor while pregnant and had clinical findings of the fetus post-BRAF inhibitor treatment. Results In total, 422 records were screened, yielding 7 cases of BRAF-inhibitor exposure during pregnancy. All patients presented with melanoma and vemurafenib was given in all but one case that used dabrafenib. Age of the mothers ranged from 25–37 years old. BRAF-inhibitor exposure occurred during the second trimester in 5 cases and in 1 case during the third trimester. Gestational age at delivery ranged from 26–36 weeks. The mother was alive at presentation in 2 of the 5 reported cases. Fetal adverse events occurred in 4 of the 7 cases including paroxysmal supraventricular tachycardia, intrauterine growth restriction, heart malformations, and delayed cranial ossification. Conclusion In this systematic review, BRAF inhibitor therapy during the second or third trimester of pregnancy may be associated with viable outcomes but carry significant potential risks to the fetus. Clinicians should approach BRAF inhibitor use during pregnancy with individualized, multi-disciplinary discussions.

    2026
    引用
    AI阅读
    加入学术空间
    4Response to the Letter to the Editor: the Role of Baseline Hepatic Function in Interpreting Adverse Events among Patients with Hepatocellular Carcinoma
    Mathieu Boulin, Marion Bellini, Steven Burlet, Théoline Fevre, Mélanie Albert,Pauline Pistre,Côme Lepage,Marianne Latournerie,Sylvain Manfredi
    2026
    引用
    AI阅读
    加入学术空间
    5The Role of Baseline Hepatic Function in Interpreting Adverse Events among Patients with Hepatocellular Carcinoma
    Duygu Ercan Uzundal
    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 3485 篇论文

    高被引作者

    作者引用发文
    Constantin A. Dasanu59390
    Marini Bernard L59212
    Perissinotti Anthony J59213
    Justin H Reid5091
    Karin M Durant5091
    Sheh-Li Chen5091
    Rami Naim Khoriaty5091
    Richard King5091
    Carole Chambers47044
    Peter Gilbar45735

    高产作者

    作者引用发文
    Constantin A. Dasanu59390
    Carole Chambers47044
    Mario L de Lemos32142
    Peter Gilbar45735
    Alexandre Chan36321
    Kolesar Jill M25721
    Younes Rahali10020
    Benyam Muluneh24920
    Bauters Tiene7719
    Melek Karakurt Eryilmaz7118

    相关期刊

    Bone marrow transplantation
    Clinical Lung Cancer
    Targeted oncology
    Immunotherapy
    Journal of the advanced practitioner in oncology
    Oncologist
    Current Treatment Options in Oncology
    ESMO Open
    Future Oncology
    Clinical Lymphoma Myeloma and Leukemia